Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This will be an uncontrolled, open-label, non-randomized, phase I study. The primary
objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety
and tolerability of Regorafenib administered orally as a single agent in Chinese patients
with advanced solid tumors. The secondary objectives are to evaluate tumor response of
patients treated with Regorafenib.